Newsfeeds - Spark Newswire

4 minute read

SQZ Biotechnologies To Present eAPC Preclinical Data Apr. 12

Today, 1:21 PM

SQZ® eAPC Platform Demonstrates that mRNA-based Expression of Co-Stimulatory CD86 and Membrane-bound IL-2 and IL-12 Dramatically Increases Antigen-Specific CD8 T Cell Activity T Cell Responses Shown Across

SQZ

3 minute read

SQZ Biotechnologies Highlights Publication Of Comprehensive Preclinical Research On Co.’s SQZ Tolerizing Antigen Carrier Platform

By Benzinga Newsdesk

Today, 1:21 PM

Tolerizing Antigen Carriers (TACs) Shown Preclinically to Combat Autoimmunity Through Deletion of Autoreactive T Cells, Anergy and Induction of Regulatory T Cells that Facilitate Potent Bystander

SQZ

2 minute read

Earnings

SQZ Biotechnologies’s Return On Capital Employed Insights

By Benzinga Insights

Today, 1:21 PM

According to Benzinga Pro data, during Q4, SQZ Biotechnologies (NYSE:SQZ) posted sales of $12.35 million. Earnings were up 47.34%, but SQZ Biotechnologies still reported an overall loss of $11.82 million.

SQZ

32 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 1:21 PM

On Monday, 524 stocks hit new 52-week lows.

AAL

19 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 1:21 PM

On Friday, 313 companies hit new 52-week lows.

AAON

5 minute read

Uncategorized

SQZ: IND Cleared for Enhanced APCs

By Zacks Small Cap Research

Today, 1:21 PM

By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT

SQZ

2 minute read

FDA
News

SQZ Biotechnologies Announces FDA Clearance Of Investigational New Drug Application For SQZ-eAPC-HPV, A Novel mRNA-based Cell Therapy For The Treatment Of HPV16 Positive Solid Tumors

By Benzinga Newsdesk

Today, 1:21 PM

SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the

SQZ